Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Serum irisin levels in new-onset type 2 diabetes.
Endoplasmic reticulum stress-induced activation of activating transcription factor 6 decreases insulin gene expression via up-regulation of orphan nuclear receptor small heterodimer partner.
This study shows that ER stress-induced activation of activating transcription factor (ATF)-6 plays an important role in the development of beta-cell dysfunction.
Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-beta signaling pathway.
DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3.
Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice
It is demonstrated for the first time that pharmacological DPP4 inhibition by evogliptin directly causes fat loss in established obese mice, providing insight into the regulation of energy storage in WAT caused by DPP 4 inhibition.
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
A Positive Feedback Loop between Sestrin2 and mTORC2 Is Required for the Survival of Glutamine-Depleted Lung Cancer Cells.
Endoplasmic Reticulum Stress and Insulin Biosynthesis: A Review
- Mi-kyung Kim, Hye-Soon Kim, In-kyu Lee, K. Park
- Biology, MedicineExperimental diabetes research
- 5 March 2012
The relationship between ER stress and diabetes and how ER stress controls insulin biosynthesis is reviewed and it is suggested that reduction of ER stress could be a therapeutic target for diabetes.
PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention
The results suggest that PAR-1622 is a selective partial activator of PPARγ and has excellent antihyperglycemic activities and a broad safety profile for fluid retention.